ADD or ADHD or What Exactly?-GIGO Part II and Other Lessons in Research with Administrative Claims
In this issue of JMCP,W ue ta l. examined administrative claims data for ap opulation of approximately 5m illion beneficiaries to identify 4,569 adult patients who received at least 1p harmacy claim for long-acting (ocmotic release oral system [OROS])-methylphenidate (MPH), mixed amphetamine salts extended release (MAS-XR), or atomoxetine, and had at least 1medical or facility claim with a diagnosis code for attention deficit disorder (ADD) or attention deficit/hyperactivity disorder (ADHD). 1 In 6m onths of followup, the median duration of therapy with OROS-MPH was 99 days versus 128 days for MAS-XR and 86 days for atomoxetine. The unadjusted median total all-cause medical cost ($1,062) for the cohort of OROS-MPH patients (n=1,452) was 1.7% less than the total all-cause medical cost ($1,080) for MAS-XR patients (n =1,554), and 16.4% less than $1,271 for atomoxetine (n=1,563). The median total all-cause medical cost for the MAS-XR cohort was also less than the cost for the atomoxetine cohort. Mean total medical cost for the atomoxetine-treated patients was higher than for either OROS-MPH or MAS-XR, but the mean costs for OROS-MPH and MAS-XR patients did not differ significantly.
Wu et al. clearly warnu st hat these area ll-cause medical costs, not ADD/ADHD-related medical costs. In fact, these authors identify for us that the difference in total medical costs among the 3cohorts is influenced by afew cost-outlier cases. The highest-cost case for OROS-MPH was $35,597 versus $134,712 for MAS-XR, and $55,950 for atomoxetine. The diagnosis codes associated with the highest cost claim for the MAS-XR outlier werechronic kidney disease (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 585.xx) and iron deficiency anemia (ICD-9-CM code 280.9). The diagnosis codes associated with the highestcost claim for the atomoxetine outlier werea cute myocardial infarction (ICD-9-CM code 410.21) and paroxysmal ventricular tachycardia (ICD-9-CM code 427.1). These cost-outlier cases have no apparent relationship to ADD/ADHD itself or to an increased rate of accidents among ADD/ADHD patients, apremise underlying the measurement of total medical costs rather than only the costs for services with an ADD/ADHD diagnosis.
Also in this issue of JMCP,O lfson et al. examine administrative claims data for 55 million beneficiaries to derive 2c ohorts of non-elderly adult (age 18-64) users of extended-release (ER)-MPH drugs (n =2,833) versus immediaterelease (IR)-MPH (n =2,289) who had at least 1o utpatient medical claim with ad iagnosis code for ADD/ADHD. This research informs us that less than one-third( 30%) of adult patients who received MPH had am edical claim for ADD or ADHD. 2 The authors' focus in this study was continuity or length of MPH therapy in adult ADD/ADHD patients, and the median duration of treatment with the index MPH medication was 68 Editorial days (95% confidence internal [CI], 65-71 days for ER-MPH versus 39 days [95% CI, 33-52 days] for IR-MPH). Although this difference of 29 days is statistically significant, the clinical and practical significance areunknown and no doubt small. Olfson et al. also inform us that only 51% of the IR-MPH patients and 61% of the ER-MPH patients had more than 1pharmacy claim for the index MPH medication. Notably, the proxy measurefor once-daily dosing employed in this study, adays supply equal to the number of units dispensed, was met by only 62% of ER-MPH patients even though ER-MPH' s8-hour duration of effect was ap remise underlying the authors' comparison of ER-MPH with IR-MPH.
On the one hand, administrative claims aggregated in relational data warehouses create wonderful opportunities for data mining to answer research hypotheses. On the other hand, data torturec an result when the limitations of claims data are underestimated. 3 Researchers using administrative claims data would do well to remember that the primarypurpose of aclaim is obtaining payment for services rendered, not supporting research activities. Previously,Barbuto warned about the danger of garbage in, garbage out (GIGO) arising from manipulation of diagnosis codes for purposes of insurance coverage for patients or for reimbursement purposes for providers. 4 For example, tension headache was replaced by migraine diagnoses in medical claims for reasons that had nothing to do with clinical presentation or actual diagnosis and everything to do with categoryo f insurance coverage.
Some of the shortcomings of administrative claims to describe clinical conditions arem ade evident by example. In literaturei nw hich authors assess utilization or costs associated with ADD or ADHD, various ICD-9-CM codes are used to identify the condition. In their examination of the total health carecosts of children with "ADHD" compared with children without ADHD and children with asthma, Chan et al. identified the ADHD sample by ICD-9-CM code 314, hyperkinetic syndrome of childhood. 5 Kemner and Lage used more stringent criteria in their study of the association between MPH formulation and health careu tilization in patients age 6a nd older. 6 Like Wu et al., Kemner and Lage identified ADHD using codes 314.00, attention deficit disorder without mention of hyperactivity,and 314.01, attention deficit disorder with hyperactivity.Y et another set of criteria was used in astudy of psychotherapeutic medication utilization by children (ages 5 to 14) with ADHD. In this analysis, Zito and colleagues attributed aphysician office visit to ADHD if it was coded with adiagnosis of 314.0, attention deficit disorder; 314.01, attention deficit disorder with hyperactivity; or 314.9, unspecified hyperkinetic syndrome; or if "restlessness" was indicated "as the reason for the visit" on adata collection form completed by the physician or office staff. 7 This variability in the diagnostic criteria employed in research possibly reflects ambiguities inherent in the coding taxonomy for this disorder.C ode 314 without modifiers is described as "hyperkinetic syndrome of childhood" but includes 5categories and even moresubcategories, if specified: attention deficit disorder (314.0), hyperkinesis with developmental delay (314.1), hyperkinetic conduct disorder (314.2), other specified manifestation of hyperkinesis (314.8), and unspecified hyperkinetic syndrome (314.9). 8 Attention deficit disorder is also known as attention deficit/ hyperactivity disorder (AD/HD or simply ADHD). The Guiding Principles for the Diagnosis and Treatment of Attention Deficit/ Hyperactivity Disorder provide as uccinct overview of the opportunities for misdiagnosis and variable quality of careinthe treatment of patients suspected of having ADD or ADHD. 9 The medical coding of ADD or ADHD can be precise or imprecise. ADHD if coded according to the apparent plain meaning of the language used in the ICD-9-CM would be identified on the medical or facility claim as 314.01 (attention deficit disorder with hyperactivity) which includes in the 2007 code descriptions "combined type", "overactivity NOS" (not otherwise specified), "predominantly hyperactive/impulsive type," and "simple disturbance of attention with overactivity." 4 But what about patients with ADD without hyperactivity? ICD-9-CM code 314.00 is defined as "attention deficit disorder without mention of hyperactivity." Thus, the taxonomy of this disorder seems to produce the oxymoronic situation that patients with ADD coded as 314.00 (no hyperactivity) areas ubset of 314 (hyperkinetic syndrome) but arec ommonly referred to as patients with "ADHD. " So, what difference does it make if one researcher uses the broad ICD-9-CM code 314 to describe "ADHD" research, encompassing ADD both with and without hyperactivity,whereas another limits the study population to the specific code 314.01 that explicitly includes hyperactivity? The answer is that we do not know.H owever,i ts eems quite likely that an arrow code such as 314.01, specific to ADHD, will identify fewer patients in an administrative claims database compared with ab road code such as 314. For those that like symmetry, at least we can say that the complexity and uncertainty in diagnosis and treatment of ADD/ADHD arematched well in the uncertainty of the clinical conditions of patients identified by ICD-9-CM code 314 and its subtypes in administrative claims.
The 3-character ICD-9-CM codes with 2-character modifiers create aseductive illusion of granularity in medical claims coding. The reality is less seductive. Although it is true that the medical diagnosis of ADD or ADHD can be precise, it is not known how many physicians spend the time necessaryt o precisely diagnosis these conditions and tailor treatment, including behavioral therapy as well as drug therapy.What is likely is that busy primaryc arep hysicians in submitting bills to payers do not typically make the fine differentiation between ICD-9-CM codes 314.00 and 314.01 for ADD without or with mention of hyperactivity,o rf or that matter,3 14.0 for ADD alone. In fact, the Superbill maintained by the American Academy of Family Practice of the codes most common in office-based, outpatient practice lists "314.00, attention deficit w/o hyper-activity" as the only code under 314. 10 So, it is probably acceptable to use ICD-9-CM code 314 with most suffixes for the purpose of research on ADD/ADHD when analyzing administrative claims, but this does not mean that the patients with medical claims having this code shareacommon pathology or,a ccordingly,t hat they would necessarily be expected to respond to the same drug treatments in the same way.
Olfson et al. describe the distribution of patients by "ADHD" subtype in their study of adult patients with "ADHD," and the group that had an index pharmacy claim for ER-MPH was different than the group that received IR-MPH ( P <0 .001). 2 Code 314.01 accounted for 46% of the patients that received ER-MPH and 39% that received IR-MPH. Code 314.00 (without mention of hyperactivity) accounted for 48% of the patients that received ER-MPH and 53% of the patients that received IR-MPH. Approximately 6% of the ER-MPH patients and 8% of the IR-MPH patients had a314 code other than 314.01 or 314.00. The clinical or practical significance of these differences is unclear.
This possibility of heterogeneity in patient populations designated with thereresults broad ICD-9-CM code 314 leads to ac hallenge in interpreting the existing literaturet hat describes research on the utilization and costs associated with ADHD. Variability of sampling methods, and possibly of billing practices in different health cares ystems, means that readers have no way of knowing whether asample population is sufficiently homogenous and representative of ADHD for the results to be clinically meaningful. Moreover,r esearchers face ac hallenge in trying to replicate the methods used in the published research when they areu ncertain or skeptical of the specific rationale underlying methodological decisions. For example, Chan et al. examined health careresource utilization in children with ADHD and concluded that adiagnosis of ADHD was similar to adiagnosis of asthma in the magnitude of consumption of health care resources. 5 The authors reported use of ICD-9-CM code "314" to identify "eligible children" with ADHD and assuage the reader by also requiring the presence of at least 2pharmacy claims for "psychostimulant medications" (e.g., MPH, MAS, or pemoline) stating, "these medications arerarely used for other conditions, except narcolepsy."
In the larger context, we need to maintain ahealthy respect for the shortcomings of administrative claims data and resist the seduction inherent in thousands of specific codes that may or may not be used precisely by coders in medical clinics where the primarypurpose of these codes is reimbursement, not differential diagnosis. This area of research in ADD/ADHD, perhaps representative of much of the field of research with administrative claims, needs al ot mores pecificity and consistency in description of the rationale underlying methods, particularly in the selection of patients by diagnosis and procedurec odes.
